Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - monobasic sodium phosphate, quantity: 1.936 g - tablet, effervescent - excipient ingredients: potassium bicarbonate; citric acid; sucrose; macrogol 4000; saccharin sodium; sodium bicarbonate; flavour - 1) hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis, and metastatic bone disease.,2) hypophosphataemia associated with vitamin d resistant rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium glycerophosphate hydrate, quantity: 6.122 g (equivalent: sodium glycerophosphate, qty 4.32 g) - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - glycophos? is indicated in adult and paediatric patients as a supplement to parenteral nutrition to meet the daily requirements of phosphate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg/ml (equivalent: dexamethasone phosphate, qty 4 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium citrate dihydrate; water for injections; sodium sulfite; disodium edetate; hydrochloric acid - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in: acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with sur

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dibasic sodium phosphate dodecahydrate, quantity: 192 mg/ml; monobasic potassium phosphate, quantity: 17.4 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 30 april 2004: treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. the cause of hypophosphataemia should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for the temporary relief of acute moderate pain and inflammation

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dexamethasone sodium phosphate, quantity: 4.4 mg (equivalent: dexamethasone phosphate, qty 4 mg) - injection - excipient ingredients: sodium citrate; creatinine; water for injections - replacement therapy:,adrenocortical insufficiency - dexamethasone has predominantly glucocorticoid activity and, therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in the following: ? acute adrenocortical insufficiency - addison's disease; bilateral adrenalectomy ? relative adrenocortical insufficiency prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should, therefore be reinstituted to help cope with stress such as that a

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dexamethasone sodium phosphate, quantity: 8.8 mg (equivalent: dexamethasone phosphate, qty 8 mg) - injection - excipient ingredients: water for injections; sodium citrate; creatinine - replacement therapy:,adrenocortical insufficiency - dexamethasone has predominantly glucocorticoid activity and, therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in the following: ? acute adrenocortical insufficiency - addison's disease; bilateral adrenalectomy ? relative adrenocortical insufficiency prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should, therefore be reinstituted to help cope with stress such as that a

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

phosphate co-op co of australia ltd - phosphorus - present as water soluble | phosphorus - present as citrate soluble | phosphorus - present as citrate insoluble | selenium | sulfur as sulfate - fertilizer, phosphorous

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

phosphate co-op co of australia ltd - phosphorus - present as water soluble | phosphorus - present as citrate soluble | phosphorus - present as citrate insoluble | selenium | sulfur as sulfate - fertilizer, phosphorous

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

phosphate co-op co of australia ltd - phosphorus - present as water soluble | phosphorus - present as citrate soluble | phosphorus - present as citrate insoluble | selenium | sulfur as sulfate - fertilizer, phosphorous